Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -0.08% | 132.19 | 0.0% | $1230.60m | |
| OCGN | Ocugen, Inc. | -2.56% | 8.74 | 0.0% | $941.39m | |
| NVAX | Novavax, Inc. | 10.59% | 174.84 | 92.9% | $613.91m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.71% | 461.57 | 2.7% | $556.12m | |
| AMGN | Amgen, Inc. | 2.62% | 227.73 | 1.3% | $540.12m | |
| GILD | Gilead Sciences, Inc. | 2.20% | 64.62 | 1.0% | $516.91m | |
| ILMN | Illumina, Inc. | -0.19% | 398.85 | 3.5% | $484.87m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 2.02% | 211.98 | 1.9% | $458.30m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 1.11% | 150.10 | 2.0% | $339.49m | |
| BIIB | Biogen, Inc. | 2.71% | 270.71 | 1.7% | $305.38m | |
| CRSP | CRISPR Therapeutics AG | -0.73% | 114.65 | 0.6% | $304.78m | |
| BNGO | BioNano Genomics, Inc. | 3.62% | 7.15 | 0.0% | $275.81m | |
| EXAS | EXACT Sciences Corp. | 0.51% | 121.64 | 18.4% | $251.13m | |
| SGEN | Seagen Inc. | 2.68% | 149.35 | 5.8% | $225.25m | |
| PACB | Pacific Biosciences of California, Inc. | 1.70% | 29.27 | 7.2% | $176.23m |
Company Profile
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. The company's Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.